239 related articles for article (PubMed ID: 34851173)
21. ECHELON-2 - brentuximab raises PTCL outcomes to new levels.
Killock D
Nat Rev Clin Oncol; 2019 Mar; 16(3):145. PubMed ID: 30602757
[No Abstract] [Full Text] [Related]
22. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Uttarwar M; Lee SY; Ren H; Kennedy DA; Shustov AR
Blood; 2018 May; 131(19):2120-2124. PubMed ID: 29507077
[TBL] [Abstract][Full Text] [Related]
23. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).
Hong J; Johnson WT; Kartan S; Gonsalves AS; Fenkel JM; Gong JZ; Porcu P
Curr Oncol; 2021 Dec; 28(6):5067-5072. PubMed ID: 34940065
[TBL] [Abstract][Full Text] [Related]
24. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
[TBL] [Abstract][Full Text] [Related]
25. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
26. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry.
Kida S; Fuji S; Morishima T; Nakata K; Miyashiro I; Ishikawa J
Int J Hematol; 2021 Aug; 114(2):246-251. PubMed ID: 33864237
[TBL] [Abstract][Full Text] [Related]
27. The aggressive peripheral T-cell lymphomas: 2013.
Armitage JO
Am J Hematol; 2013 Oct; 88(10):910-8. PubMed ID: 24078271
[TBL] [Abstract][Full Text] [Related]
28. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
Dupuis J; Morschhauser F; Ghesquières H; Tilly H; Casasnovas O; Thieblemont C; Ribrag V; Bossard C; Le Bras F; Bachy E; Hivert B; Nicolas-Virelizier E; Jardin F; Bastie JN; Amorim S; Lazarovici J; Martin A; Coiffier B
Lancet Haematol; 2015 Apr; 2(4):e160-5. PubMed ID: 26687958
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma.
Best JH; Hornberger J; Proctor SJ; Omnes LF; Jost F
Value Health; 2005; 8(4):462-70. PubMed ID: 16091023
[TBL] [Abstract][Full Text] [Related]
30. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Hornberger JC; Best JH
Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
32. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
33. NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY.
Kriachok I; Tytorenko I; Shudrak N; Aleksik O; Stepanishyna Y; Kadnikova T; Pastushenko Y; Shokun N; Rudiyk T; Bushuieva M
Exp Oncol; 2024 Feb; 45(4):474-482. PubMed ID: 38328842
[TBL] [Abstract][Full Text] [Related]
34. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
Gallamini A; Zaja F; Patti C; Billio A; Specchia MR; Tucci A; Levis A; Manna A; Secondo V; Rigacci L; Pinto A; Iannitto E; Zoli V; Torchio P; Pileri S; Tarella C
Blood; 2007 Oct; 110(7):2316-23. PubMed ID: 17581918
[TBL] [Abstract][Full Text] [Related]
35. Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population.
Shirouchi Y; Yokoyama M; Fukuta T; Uryu H; Nishimura N; Mishima Y; Inoue N; Tsuyama N; Takeuchi K; Terui Y
Leuk Lymphoma; 2021 Aug; 62(8):1869-1876. PubMed ID: 33688781
[TBL] [Abstract][Full Text] [Related]
36. Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma.
Liang X; Guo L; Hu X; Li S; Wen S
Medicine (Baltimore); 2021 Apr; 100(13):e25194. PubMed ID: 33787601
[TBL] [Abstract][Full Text] [Related]
37. Burden of illness and treatment patterns among patients with peripheral T-cell lymphoma in the US healthcare setting.
Petrilla AA; Shah A; Feliciano J; Woolery J; LeBlanc TW
Curr Med Res Opin; 2021 Jul; 37(7):1189-1197. PubMed ID: 33944646
[TBL] [Abstract][Full Text] [Related]
38. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Savage KJ; Horwitz SM; Advani R; Christensen JH; Domingo-Domenech E; Rossi G; Morschhauser F; Alpdogan O; Suh C; Tobinai K; Shustov A; Trneny M; Yuen S; Zinzani PL; Trümper L; Ilidge T; O'Connor OA; Pro B; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Iyer S
Blood Adv; 2022 Oct; 6(19):5550-5555. PubMed ID: 35470385
[TBL] [Abstract][Full Text] [Related]
39. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
40. [Current treatment strategies for peripheral T-cell lymphoma].
Munakata W
Rinsho Ketsueki; 2021; 62(8):1112-1120. PubMed ID: 34497198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]